دورية أكاديمية
أعرض في EDS

Moderately-differentiated Ovarian Sertoli-Leydig Cell Tumor With a Concurrent Serous Borderline Tumor in a 16-year-old Girl.

التفاصيل البيبلوغرافية
العنوان: Moderately-differentiated Ovarian Sertoli-Leydig Cell Tumor With a Concurrent Serous Borderline Tumor in a 16-year-old Girl.
المؤلفون: Bhardwaj S, Banet N, Gaston EC
المصدر: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists [Int J Gynecol Pathol] 2024 Mar 01; Vol. 43 (2), pp. 140-144. Date of Electronic Publication: 2023 Jul 18.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8214845 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7151 (Electronic) Linking ISSN: 02771691 NLM ISO Abbreviation: Int J Gynecol Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York : Raven Press, c1982-
مواضيع طبية MeSH: Sertoli-Leydig Cell Tumor*/diagnosis , Sertoli-Leydig Cell Tumor*/surgery , Sertoli-Leydig Cell Tumor*/pathology , Ovarian Neoplasms*/pathology , Sex Cord-Gonadal Stromal Tumors* , Cystadenoma, Serous* , Precancerous Conditions*, Female ; Humans ; Child ; Middle Aged ; Adolescent
مستخلص: Sertoli-Leydig cell tumors (SLCT) are rare tumors of the ovary with a peak incidence in the second to third decade of life. Serous borderline tumors (SBT) are epithelial ovarian neoplasms which occur at a median age of 50 years. A co-occurrence of SLCT and SBT has not yet been reported. Here, we describe a case of a 16-year-old girl who presented with irregular menses, virilization, and an abdominopelvic mass. The mass was surgically removed and an intraoperative consultation revealed an 18.5 cm solid and cystic ovarian mass with the presence of co-existing SLCT and SBT. The diagnosis was confirmed on permanent sections after extensive sampling and immunohistochemical stains. The SLCT showed positive staining for calretinin, inhibin, CD99, and androgen receptor. MART-1 immunostain highlighted the Leydig cells. The SBT showed classic features including hierarchically branching papillae lined by stratified serous epithelium. This pediatric case is the first reported case of a Sertoli-Leydig cell tumor arising in association with a serous borderline tumor.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2023 by the International Society of Gynecological Pathologists.)
References: WHO Classification of Tumors Editorial Board. Female genital Tumors, 5th edn.. Lyon (France): International Agency for Research on Cancer; 2020. WHO classification of Tumors series. Accessed May 24, 2023. https://publications.iarc.fr/592 .
Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors: a clinicopathological analysis of 207 cases. Am J Surg Pathol 1985;9:543–69.
de Kock L, Terzic T, McCluggage WG, et al. DICER1 mutations are consistently present in moderately and poorly differentiated Sertoli-Leydig cell tumors. Am J Surg Pathol 2017;41:1178–87.
Roth LM. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Int J Gynecol Pathol 2006;25:199–215.
Young RH, Prat J, Scully RE. Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases. Cancer 1982;50:2448–56.
Skírnisdóttir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008;123:1897–901.
Fischerova D, Zikan M, Dundr P, et al. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist 2012;17:1515–33.
Childress KJ, Patil NM, Muscal JA, et al. Borderline ovarian tumor in the pediatric and adolescent population: a case series and literature review. J Pediatr Adolesc Gynecol 2018;31:48–54.
Vang R, Hannibal CG, Junge J, et al. Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases. Am J Surg Pathol 2017;41:725–37.
Chui MH, Xing D, Zeppernick F, et al. Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma. Am J Surg Pathol 2019;43:1462–72.
Chernecky CC, Berger BJ. Laboratory tests and diagnostic procedures—E-Book. Elsevier Health Sciences; 2012:1059–62.
Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. Curr Opin Obstet Gynecol 2007;19:22–6.
Seo EJ, Kwon HJ, Shim SI. Ovarian serous cystadenoma associated with Sertoli-Leydig cell tumor—a case report. J Korean Med Sci 1996;11:84–7.
Stacher E, Pristauz G, Scholz HS, et al. Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report. Int J Gynecol Pathol 2010;29:419–22.
Buza N, Wong S, Hui P. FOXL2 mutation analysis of ovarian sex cord-stromal tumors: genotype-phenotype correlation with diagnostic considerations. Int J Gynecol Pathol 2018;37:305–15.
Karnezis AN, Wang Y, Keul J, et al. DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumors. Am J Surg Pathol 2019;43:628–38.
SCR Disease Name: Androblastoma of ovary
تواريخ الأحداث: Date Created: 20230810 Date Completed: 20240209 Latest Revision: 20240627
رمز التحديث: 20240627
DOI: 10.1097/PGP.0000000000000971
PMID: 37562020
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-7151
DOI:10.1097/PGP.0000000000000971